Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Power3 Medical Products Inc.

Division of Amarantus BioScience Holdings Inc.
www.power3medical.com

Latest From Power3 Medical Products Inc.

Deals Shaping The Medical Industry, February 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, November 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Medical Device Deals Update, March 2012

A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.

Medical Device

Deals In Depth: January 2012

Forma Therapeutics penned an $815 million oncology drug discovery alliance with BI. BMS and Amgen spent over $1 billion each to purchase Inhibitex and Micromet, respectively. And AngioDynamics acquired Navilyst Medical for $367 million. Biopharma and device financing both increased in January from the previous month.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Cancer
  • Neurology, Nervous System
  • Alias(es)
  • Surgical Safety Products Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amarantus BioScience Holdings Inc.
  • Amarantus Bioscience Inc.
  • Senior Management
  • Helen R Park, Interim CEO
    Ira L Goldknopf, PhD, CSO
  • Contact Info
  • Power3 Medical Products Inc.
    Phone: (713) 417-9954
    26202 Oakridge Dr.
    The Woodlands, TX 77380
    USA
UsernamePublicRestriction

Register